After joining the Qima Group in 2018 and 2019, Bioalternatives and Synelvia, providers in the field of efficacy testing, now operate under the name Qima Life Sciences to carry the group's ambition in life sciences.
Bioalternatives and Synelvia, preclinical contract research and innovation laboratories for the cosmetics and dermatology industries, announce their name change to the single brand Qima Life Sciences. After joining Qima in 2018 (Bioalternatives) and 2019 (Synelvia), the two companies have progressively joined forces to develop the group's life sciences business, and will now operate under a single banner that reflects Qima's ambition.
Qima Life Sciences offers analytical services adapted to skin biology. The range of tests extends from virtual screening in silico to the bioanalysis of non-invasive clinical samples, through to the in vitro and ex vivo. The tests are performed in France, on two sites in Gençay (Vienne) and Labège (Haute-Garonne). With 60 experts and two 1000 m² laboratories, the company helps the marketing and R&D departments of major European and American cosmetic and pharmaceutical groups to innovate in the conceptualization of their projects and to substantiate and support their product claims.
In parallel with this name change, the company is inaugurating its new laboratories and offices. It will also launch its new range of tests for the study of skin immuno-inflammation at Cosmetic 360.
"Life sciences are a priority pillar of our growth strategy for the group, and it was time for our expert teams in these fields to join the Qima banner, comments Sébastien Breteau, president and founder of Qima. Alongside our FMCG and food businesses, Qima Life Sciences contributes to our mission to provide smart solutions so consumers can trust the products they buy."
"This is an important moment in the life of Bioalternatives and Synelvia, adds Guillaume Tenca, General Manager of Qima Life Sciences. We can now offer our customers a unique face, and focus our efforts on providing them with ever more innovative support in their research and development efforts."
